Loading organizations...
Alveus Therapeutics is a biotechnology company developing novel obesity and metabolic disease treatments, with headquarters in Philadelphia, Pennsylvania, and research operations in Copenhagen, Denmark. The startup focuses on building a portfolio of drugs designed to improve the tolerability and durability of existing weight loss therapies, including its lead GLP-1/GIP antagonist candidate, ALV-100, which is advancing toward Phase 2 clinical testing. Operating with fewer than 50 employees, the enterprise recently secured $160 million in Series A funding backed by prominent institutional investors such as Andera Partners, Omega Funds, and Sanofi Capital. The executive leadership team leverages prior metabolic drug development experience from major pharmaceutical corporations like Novo Nordisk and Eli Lilly to advance this clinical pipeline. Alveus Therapeutics was officially founded in 2024 by New Rhein Healthcare Investors and its managing partner, Nayan Parekh.
Alveus Therapeutics has raised $357.0M across 2 funding rounds.
Alveus Therapeutics has raised $357.0M in total across 2 funding rounds.
Alveus Therapeutics has raised $357.0M across 2 funding rounds. Most recently, it raised $197.0M Series A Extension in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 3, 2026 | $197M Series A Plus | Andera Partners, NEW Rhein Healthcare Investors | Avego Bioscience Capital, Rafaèle Tordjman, Kurma Partners, Novo Holdings, Omega Funds, Sanofi Ventures | Announced |
| Jan 8, 2026 | $160M Series A | JAN VAN DEN Bossche, Nayan Parekh, Claudio Nessi | Avego Bioscience Capital, Kurma Partners, Sanofi Ventures | Announced |
Alveus Therapeutics has raised $357.0M in total across 2 funding rounds.
Alveus Therapeutics's investors include Andera Partners, New Rhein Healthcare Investors, Avego Bioscience Capital, Rafaèle Tordjman, Kurma Partners, Novo Holdings, Omega Funds, Sanofi Ventures, Jan Van den Bossche, Nayan Parekh, Claudio Nessi.
